Introduction {#S1}
============

The spinocerebellar ataxias (SCAs) are a diverse group of neurodegenerative diseases that share clinical phenotypes including impaired balance and motor coordination, Purkinje cell death and cerebellar atrophy ([@B79]; [@B170]). The global prevalence of SCA is estimated at three affected patients per 100 000 individuals ([@B177]), with higher prevalence in some geographical regions ([@B79]; [@B202]).

For most cerebellar ataxias, pathology can be attributed to an underlying genetic mutation. These known genetic causes include glutamine-encoding CAG repeat expansions (polyQ), untranslated repeat expansions, DNA rearrangements and conventional mutations, such as missense mutations, insertions or deletions ([@B79]; [@B163]). As with many other inherited disorders, there are several different cellular processes and pathways that contribute to disease pathogenesis. Such processes and pathways include transcriptional dysregulation, RNA toxicity, proteostasis, protein aggregation and altered neuronal activity ([@B79]; [@B163]). Despite vast heterogeneity in causative genes across the different SCAs, there is considerable overlap in the cellular processes affected, producing similar neuropathology and clinical phenotypes. Nevertheless, our understanding of the contribution of the various pathogenic pathways or mechanisms to each SCA disease remains limited.

Dysfunction of Purkinje cells and consequent dysfunction of cerebellar circuitry is a common feature of the SCAs, regardless of the disease-causing gene mutation ([@B108]; [@B79]). Despite ubiquitous expression of most SCA-causing genes throughout the brain, pathology is most prominent within the cerebellum ([@B18]). This suggests that neuronal populations within the cerebellum, particularly Purkinje cells, may be more susceptible to changes in transcription, translation, protein quality control and signaling than other neuronal cell types. Furthermore, Purkinje cell degeneration has been found to precede other important disease phenotypes, including movement and balance deficits. This review will discuss why the cerebellum may be particularly vulnerable or susceptible to the cellular and mechanistic insults caused by SCA-causing disease mutations.

Clinical Classification of the Spinocerebellar Ataxias {#S2}
======================================================

Currently, there are over forty-five distinct types of SCA that have been clinically described ([Table 1](#T1){ref-type="table"}). The most common clinical symptoms associated with SCA include gait ataxia and uncoordinated movements ([@B202]). In most SCA patients, gait ataxia is the first sign of dysfunction. Other symptoms often associated with the different SCAs include dysarthria, nystagmus, vision impairments, pyramidal and extrapyramidal signs, ophthalmoplegia and cognitive deficits ([@B202]). Despite the commonality of the presence of ataxia, there is nevertheless considerable variability in disease symptoms across the SCA diseases, leading these diseases to be clinically classified into subtypes; autosomal dominant cerebellar ataxia type I, II and III.

###### 

Summary of each identified form of Spinocerebellar ataxia, including causative gene, type of genetic mutation, effect of genetic mutation, clinical symptoms and key references.

  SCA        Gene            Mutation                                                       Effect of mutation                                                                                           Impaired/Altered processes                                                                                                                                                                              Clinical symptoms                                                                                                                                             Clinical classification   Key references
  ---------- --------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ---------------------------------------------
  SCA1       *ATXN1*         Trinucleotide repeat expansion (39-83 repeats)                 Hypothesized gain-of-function. Downregulation of genes associated with maintenance of calcium homeostasis.   Dysregulation of transcription. Downstream glutamate signaling is indirectly dysregulated, resulting in reduced Purkinje cell firing frequency.                                                         Pyramidal signs, peripheral neuropathy and opthalmoparesis. Loss of \> 75% of Purkinje cells.                                                                 Type I                    [@B156]; [@B129]; [@B121]; [@B169]; [@B176]
  SCA2       *ATXN2*         Trinucleotide repeat expansion (32-79 repeats)                 Hypothesized toxic gain-of-function.                                                                         Toxic enhancement of mGluR and IP3R1 function, increasing calcium release and Purkinje cell hyperexcitability.                                                                                          Hyporeflexia, dysarthria, tremor and slow eye movements. Loss of \> 75% of Purkinje cells.                                                                    Type I                    [@B97]; [@B171]; [@B180]; [@B131]; [@B144]
  SCA3       *ATXN3*         Trinucleotide repeat expansion (\> 40 repeats)                 Hypothesized loss of deubiquitinase activity. Gain of IP3R1 function.                                        Longer ubiquitin chains and dysregulation of transcription. Mutant ataxin-3 interacts with IP3R1, causing increased calcium release and Purkinje cell excitability.                                     Progressive gait imbalance, speech difficulties, ocular motor difficulties, spasticity, dystonia, dysarthria and dysphagia. Loss of ∼25% of Purkinje cells.   Type I                    [@B111]; [@B162]; [@B32]
  SCA4       Chromosome 16   Unknown                                                        *NHE5* is a hypothesized candidate gene.                                                                     Hypothesized to disrupt Na^+^/H^+^ exchange in skeletal muscles, leading to altered intracellular pH and cell death.                                                                                    Sensory peripheral neuropathy, extensor plantar responses, areflexia, dysarthria.                                                                             Type I                    [@B65]; [@B84]
  SCA5       *SPTBN2*        Missense mutation                                              Dominant negative effects on sodium channel complexes. Impaired mGluR1 and EAAT4 expression.                 Impaired long-term potentiation of Purkinje cells. Decreased responsiveness to mGluR1 and excessive glutamate presence. inducing toxicity. Abnormal Purkinje cell dendritic development.                Pure cerebellar ataxia, with incoordination of extremities and slurred speech. Relatively mild severity.                                                      Type III                  [@B172]; [@B95]; [@B165]; [@B6]
  SCA6       *CACNA1A*       Trinucleotide repeat expansion (19-33 repeats)                 Toxic loss of α1ACT function, a transcription factor.                                                        Reduced expression of genes critical to Purkinje cell development and survival.                                                                                                                         Pure cerebellar ataxia. Loss of \> 75% of Purkinje neurons.                                                                                                   Type III                  [@B235]; [@B143]; [@B205]; [@B55]; [@B56]
  SCA7       *ATXN7*         Trinucleotide repeat expansion (38-150 repeats).               Loss of chromatin remodeling and Bergmann glial cell function.                                               Impaired regulation of transcription and glutamate-reuptake, resulting in dysfunction of Purkinje cells and retinal cells.                                                                              Dystrophy of retinal rods and cones, resulting in vision loss, hypoacusia and hypotonia.                                                                      Type II                   [@B45]; [@B16]; [@B81]; [@B138]
  SCA8       *ATXN8*         Non-coding trinucleotide repeat expansion (107-127 repeats)    Toxic gain-of-function (RNA and protein products).                                                           Repeat-associated non-ATG (RAN) translation. Formation of ribonuclear inclusions which localize to RNA binding protein Mbn11.                                                                           Cognitive dysfunction, myotonic dystrophy, pyramidal and sensory signs.                                                                                       Type I                    [@B118]
  SCA10      *ATXN10*        Non-coding pentanucleotide repeat (800-4500 repeats)           Gain of toxic RNA function. Loss of hnRNPK function (RNA splicing factor).                                   Neuritogensis, accumulation of aggregated RNA and increased activation of apoptotic cascades.                                                                                                           Ataxic gait, dysarthria, nystagmus, hypotonia and occasional epilepsy.                                                                                        Type I                    [@B141]; [@B236]; [@B142]
  SCA11      *TTBK2*         Frameshift mutation                                            Loss of TTBK2 function, resulting in reduced TTBK2 transcript levels.                                        Mutation causes loss of function, impacting on tau regulation/phosphorylation and neuronal integrity.                                                                                                   Pure cerebellar ataxia, pyramidal signs                                                                                                                       Type III                  [@B87]
  SCA12      *PPP2R2B*       Non-coding trinucleotide repeat expansion (55-78 repeats)      Unknown                                                                                                      Yet to be clarified, however hypothesized mitochondrial dysfunction and increased oxidative stress.                                                                                                     Gait ataxia, upper limb postural tremor, hyperreflexia, parkinsonian features and dementia.                                                                   Type I                    [@B86]; [@B155]
  SCA13      *KCNC3*         Missense mutation                                              Both loss and gain of Kv3.3 function.                                                                        Activation curve of Kv3.3 shifted toward channel opening and slowed channel closing, disrupting Purkinje cell excitability and function.                                                                Cerebellar ataxia, dysarthria, nystagmus, pyramidal signs, delayed motor and cognitive development.                                                           Type I                    [@B83]; [@B226]; [@B63]; [@B99]
  SCA14      *PRKCG*         Missense mutation                                              Both loss and gain of PKCγ function.                                                                         Altered activity PKCγ, resulting in altered extracellular Ca^2+^ entry through TRPC3 receptors.                                                                                                         Cerebellar ataxia, myoclonus and task-specific dystonia.                                                                                                      Type I                    [@B31]; [@B212]; [@B1]
  SCA15/16   *ITPR1*         Missense mutation                                              Loss of IP3R1 function.                                                                                      Reduced intracellular calcium signaling, decreasing Purkinje cell excitability.                                                                                                                         Pure cerebellar ataxia, tremor and cognitive impairment                                                                                                       Type III                  [@B200]; [@B208]; [@B100]
  SCA17      *TBP*           Trinucleotide repeat expansion (47-63 repeats)                 Altered TATA-box binding protein function.                                                                   Impaired transcription. Effect on Purkinje cells is still an area of active research.                                                                                                                   Gait ataxia, dysmetria, hyperreflexia, parkinsonian features and dementia.                                                                                    Type I                    [@B150]
  SCA18      *IFRD1*         Missense mutation                                              Hypothesized loss of function.                                                                               Abnormalities in IFRD1 protein folding, increased nuclear localization and hypothesized impairments to normal transcriptional co-repressor function.                                                    Gait ataxia, sensory neuropathy, dysmetria, dysarthria and nystagmus.                                                                                         Type I                    [@B20]; [@B21]; [@B128]
  SCA19/22   *KCND3*         Missense mutation                                              Loss of Kv4.3 function.                                                                                      Kv4.3 mislocalization, resulting in lack of expression at PC synapse, impairing long term potentiation                                                                                                  Cerebellar ataxia, hyporeflexia and myoclonic movements.                                                                                                      Type I                    [@B213]; [@B41]; [@B57]; [@B124]
  SCA20      Chromosome 11   Genomic duplication                                            Hypothesized gain of *DAGLA* function.                                                                       *DAGLA* is expressed in Purkinje cells and acts to weaken glutamate signaling.                                                                                                                          Cerebellar ataxia, dysarthria and spasmodic dysphonia.                                                                                                        Type I                    [@B113]
  SCA21      *TMEM240*       Missense mutation and/or stop mutation                         Hypothesized gain of function.                                                                               Synaptic transmembrane protein, function currently unknown.                                                                                                                                             Slow progressing ataxia, mild to severe cognitive impairment and parkinsonian features.                                                                       Type I                    [@B51]; [@B218]; [@B49]
  SCA23      *PDYN*          Missense mutation                                              Increase in DynA production, toxic gain-of-function.                                                         Increased opioid and glutamate signaling, producing downstream glutamate toxicity.                                                                                                                      Gait ataxia, dysarthria, dysmetria and hyperreflexia.                                                                                                         Type I                    [@B214]; [@B7]
  SCA25      Chromosome 2    Unknown                                                        Unknown                                                                                                      Candidate gene: *CRIPT2*. Encoded protein is involved in postsynaptic architecture.                                                                                                                     Cerebellar ataxia, peripheral neuropathy.                                                                                                                     Type I                    [@B198]
  SCA26      *EEF2*          Missense mutation                                              Increased rate of protein frameshift during translation.                                                     Structural defect in eEF2 protein, resulting in impaired translation and reduced proteostatic capacity.                                                                                                 Pure cerebellar ataxia and dysarthria. Loss of \> 75% of Purkinje cells.                                                                                      Type III                  [@B233]; [@B80]
  SCA27      *FGF14*         Missense mutation                                              Loss of Nav1.6 expression, dominant negative effect on Cav2.1 and Cav2.2.                                    Reduced expression of ion channels, leading to reduced ion influx and suppression of Purkinje cell output.                                                                                              Early onset upper limb postural tremor, dyskinesia, dystonia and slowly progressing CA.                                                                       Type I                    [@B210]; [@B119]; [@B192]; [@B230]
  SCA28      *AFG3L2*        Missense mutation                                              Dominant-negative and loss-of-function effects.                                                              Loss of mitochondrial ATP-dependent protease activity, resulting in reduced degradation of misfolded proteins within the mitochondria and impaired mitochondrial function.                              Ataxic gait, nystagmus, ptosis and opthalmoparesis.                                                                                                           Type I                    [@B26]; [@B137]; [@B27]
  SCA29      *ITPR1*         Missense mutation                                              Dominant negative effect on IP3R1.                                                                           Downregulation of IP3R1, and decreased calcium release. One mutation found to enhance calcium release.                                                                                                  Gait ataxia, dysarthria, ophthalmoplegia, pyramidal and extrapyramidal dysfunction and cognitive impairments.                                                 Type I                    [@B90]; [@B5]
  SCA30      Chromosome 4    Unknown                                                                                                                                                                                                                                                                                                                                                                             Slow progressing, pure cerebellar ataxia with minor pyramidal signs.                                                                                          Type III                  [@B199]
  SCA31      Chromosome 16   Intronic pentanucleotide repeat expansion                      Hypothesized RNA-mediated toxic gain-of-function.                                                            Repeat-expanded RNA found to localize with centromeres. Unknown effect on Purkinje cells.                                                                                                               Pure cerebellar ataxia, relatively late onset (average age: 61.2 years).                                                                                      Type III                  [@B157]; [@B181]
  SCA34      *ELOVL4*        Missense mutation                                              Unknown                                                                                                      Impaired differentiation of skin cells. Hypothesized impacts on proteostasis.                                                                                                                           Ataxic gait, nystagmus, dysarthria and erythron-keratodermia.                                                                                                 Type I                    [@B73]; [@B25]; [@B158]
  SCA35      *TGM6*          Missense mutation                                              Loss of transglutaminase 6 enzymatic activity.                                                               Disrupted proteostasis; induction of unfolded protein response, formation of insoluble protein aggregates.                                                                                              Ataxic gait, mild dysarthria and tremor, dysmetria and hyperreflexia.                                                                                         Type I                    [@B219]; [@B206]
  SCA36      *NOP56*         Intronic hexanucleotide repeat expansion (1500-2000 repeats)   Toxic gain-of-function (RNA toxicity).                                                                       RAN translation. Decreased transcription of gene 19bp upstream of expansion, *MIR1292*. Decreased *MIR1292* associated with upregulation of glutamate receptors and perturbed Purkinje cell function.   Cerebellar ataxia with motor neuron involvement, dysarthria and tongue atrophy.                                                                               Type I                    [@B114]; [@B96]
  SCA37      *DAB1*          Intronic pentanucleotide repeat expansion (31-75 repeats)      Hypothesized RNA-mediated toxicity.                                                                          Formation of RNA aggregates. Protein involved in maturation of dendritic spines and synaptogenesis of cerebellar granule cells.                                                                         Pure cerebellar ataxia with altered vertical eye movements.                                                                                                   Type III                  [@B188]; [@B185]
  SCA38      *ELOVL5*        Missense mutation                                              Hypothesized toxic gain-of function.                                                                         Disrupted lipid metabolism, mislocalization of ELOVL5 protein and activation of unfolded protein response.                                                                                              Ataxic gait, nystagmus, dysarthria and mild sensory neuropathy.                                                                                               Type I                    [@B53]
  SCA39      Chromosome 11   Chromosomal duplication                                        Unknown                                                                                                                                                                                                                                                                                                              Cerebellar ataxia, dysmetria, spasticity and dysarthria. Motor impairments from infancy.                                                                                                [@B104]
  SCA40      *CCDC88C*       Missense mutation                                              Hypothesized toxic gain-of-function.                                                                         Impaired WNT signaling, JNK hyperphosphorylation, proteolytic cleavage of caspase 3 and increased apoptosis.                                                                                            Ataxic gait, dysarthria, hyperreflexia, ocular dysmetria and tremor.                                                                                          Type I                    [@B207]
  SCA41      *TRPC3*         Missense mutation                                              Toxic gain of TRPC3 function.                                                                                Enhanced permeability of calcium, resulting in increased activation of mGluRs and glutamate induced toxicity.                                                                                           Pure cerebellar ataxia.                                                                                                                                       Type III                  [@B66]
  SCA42      *CACNA1G*       Missense mutation                                              Loss of Cav3.1 function.                                                                                     Impairments to Purkinje cell rebound bursting, requiring higher current influx to evoke Purkinje cell depolarization.                                                                                   Ataxic gait, dysarthria nystagmus, pyramidal signs and cognitive impairment.                                                                                  Type I                    [@B43]; [@B147]; [@B77]
  SCA43      *MME*           Missense mutation                                              Hypothesized gain-of-function.                                                                               Hypothesized interaction with Schwann cells.                                                                                                                                                            Cerebellar ataxia and peripheral neuropathy.                                                                                                                  Type I                    [@B50]
  SCA44      *GRM1*          Missense mutation                                              Toxic gain of mGluR1 function.                                                                               Excessive mGluR1 signaling resulting in increased downstream calcium signaling.                                                                                                                         Cerebellar ataxia, corticospinal tract involvement, dysarthria, dysphagia and dysmetria.                                                                      Type I                    [@B227]
  SCA45      *FAT2*          Multiple missense mutation                                     Unknown                                                                                                      Hypothesized role in autophagy.                                                                                                                                                                         Pure cerebellar ataxia                                                                                                                                        Type III                  [@B153]
  SCA46      *PLD3*          Missense mutation                                              Hypothesized loss of function.                                                                               Hypothesized interaction with β-amyloid.                                                                                                                                                                Cerebellar ataxia and peripheral neuropathy.                                                                                                                  Type I                    [@B209]; [@B153]
  SCA47      *PUM1*          Missense mutation                                              Loss of PUM1function.                                                                                        PUM1 is a RNA binding protein, which interacts with ataxin-1. Reduced expression of *PUM1* results in increased expression of *ATXN1*.                                                                  Slow progressing, pure CA with ataxic dysarthria, limb dysmetria and impaired gait.                                                                           Type III                  [@B71]; [@B120]
  SCA48      *STUB1*         Frame shift mutation                                           Impaired function of CHIP, an E3 ubiquitin ligase.                                                           Hypothesized dysfunction of protein quality control pathways.                                                                                                                                           Adult-onset cerebellar ataxia, dystonia, epilepsy, parkinsonism and cognitive impairments.                                                                    Type I                    [@B70]; [@B46]; [@B126]; [@B159]

Autosomal dominant cerebellar ataxia Type I represents a mixed group of ataxias (as outline in [Table 1](#T1){ref-type="table"}), involving presentation of a broad array of neurological symptoms in addition to cerebellar ataxia ([@B79]). Additional symptoms include upper limb postural tremor in SCA12 and SCA27, myoclonus and task-specific dystonia in SCA14, sensorineural hearing loss in SCA37 and cognitive impairments in SCA18, SCA13 and SCA21. The most prevalent SCAs (SCA1-3) are caused by trinucleotide repeat expansion within affected genes, leading to polyglutamine (polyQ) tract expansion. The SCAs caused by trinucleotide repeat expansions are typically more severe, with faster progression and multiple sites of neuropathology ([@B178]; [@B138]). Further, in the trinucleotide repeat SCAs, age of onset and disease severity are correlated with the length of the repeat expansion ([@B161]).

Autosomal dominant cerebellar ataxia Type II is a highly specialized ataxia, whereby classical cerebellar ataxia is accompanied by retinal degeneration ([@B79]). Currently, SCA7 is the only spinocerebellar ataxia clinically categorized in this specialized sub-group. SCA7 patients experience progressive blindness due to dystrophy of retinal rods and cones ([@B45]; [@B16]).

Autosomal dominant cerebellar ataxia Type III, also known as pure cerebellar ataxias, are disease states in which the cerebellar ataxia is the sole or predominant manifestation of neurological disease ([@B79]). Examples of Type III SCAs are outlined in [Table 1](#T1){ref-type="table"}. Whilst patients may initially present with pure cerebellar pathology, other neurological symptoms such as extrapyramidal symptoms or cognitive deficits may develop as the disease progresses. For example, SCA6 is caused by a polyglutamine trinucleotide repeat expansion within the causative gene, similar to SCA1, SCA2 and SCA3, but it is considered as a pure cerebellar ataxia as its pathology is predominately confined to the cerebellum. Further, SCA6 is unique compared to other polyQ SCAs in that a shorter repeat length (21-33 repeats) has been found to cause disease ([@B235]; [@B143]; [@B205]).

What Pathophysiological Changes Within the Cerebellum Underlie SCA Diseases? {#S3}
============================================================================

The neuropathology of SCA diseases is varied and complex; in some SCAs, pathology is restricted to the cerebellum whilst other SCAs yield more extensive neuropathology, affecting efferent regions including the thalamus, red nucleus and spinal cord ([@B163]). Nevertheless, degeneration and ultimate loss of cerebellar neurons is a neuropathological hallmark of the SCA diseases. Once most spinocerebellar patients display motor symptoms, irreversible damage has already occurred within the brain ([@B138]). As the disease progresses heterotopy, altered spatial organization of cells, and atrophy can be detected within the cerebellum by neuroimaging and histological analysis ([@B138]).

Dysfunction and Degeneration of Purkinje Cells {#S3.SS1}
----------------------------------------------

The cerebellum is the second largest brain area, second to the cerebral cortex, but it contains more neurons than the rest of the brain combined ([@B170]). Since the early 20th century, the cerebellum has been implicated in the control and timing of movement. Functionally, the cerebellum is critical to ensuring movements are performed precisely, in a coordinated and timely manner ([@B36]). More recently, the cerebellum has also been appreciated for its role in higher order cognitive and emotional processes ([@B182]).

In order to achieve smooth and balanced muscle movement the cerebellum receives input from the sensory systems, the spinal cord, and other parts of the brain. Firstly, the cerebellum receives input from the inferior olive in the form of climbing fibers and the spinocerebellar tract in the form of mossy fibers ([@B105]). These inputs project, both directly and indirectly, to the deep cerebellar nuclei (DCN) present within the white matter of the cerebellum.

Superficial to the DCN are three laminar structures called the granular, Purkinje and molecular layers. The innermost layer, the thick granular layer, is densely packed with granule cells. Superficial to this, is the Purkinje layer, a narrow zone that contains the cell bodies of Purkinje cells, relatively large inhibitory neurons that act to modify activation of the DCN ([@B91]). The outermost layer called the molecular layer contains the expansive dendritic trees of Purkinje cells and the parallel fibers of the granule cells intercepting these dendrites at right angles. This layer also contains two types of interneurons called stellate cells and basket cells. Together the excitatory parallel fibers and inhibitory (γ-aminobutyric acid, GABAergic) stellate and basket cells regulate firing of Purkinje cells. From there, the Purkinje cells are the sole neuronal output from the cerebellar cortex, sending GABAergic inputs to the DCN and in turn projecting to the thalamus, brainstem and motor cortex ([@B91]).

Dysfunction of Purkinje cells and cerebellar circuitry is thought to be the predominant overlapping pathogenic mechanism across SCA diseases, eliciting hallmark ataxic symptoms ([@B108]). In fact, Purkinje cells are the most affected neuronal population in the Spinocerebellar ataxias, with some SCAs resulting in loss of more than 75% of the total Purkinje cell population ([@B108]). The cause of this neurodegeneration of cerebellar Purkinje cells is not well understood but may be due to increased susceptibility to genetic or functional insults than other neuronal cell types ([@B79]). Healthy Purkinje cells display autonomous pacemaker activity, firing in absence of synaptic input and with very little variability between spiking intervals ([@B78]; [@B145]; [@B163]; [@B91]).

Purkinje cells provide mostly inhibitory inputs to neurons within the DCN, which are critical for planning, performing and fine-tuning motor actions ([@B78]; [@B123]; [@B91]; [Figure 1A](#F1){ref-type="fig"}). If firing of Purkinje cells were impaired or dysfunctional, DCN neurons could become disinhibited, increasing excitatory tone within the cerebellum ([@B145]; [Figure 1B](#F1){ref-type="fig"}). Increased excitation of DCN neurons would result in increased excitatory input from the DCN to motor centers, causing impairments to motor performance, specifically coordination and fine-tuning of movement ([@B108]; [@B145]). Indeed, optogenetic silencing of Purkinje cell output in mice evokes increased bursting within DCN neurons and rapid body movements ([@B78]; [@B123]). In contrast, increased excitation of Purkinje cells would result in an overall increase in inhibitory tone, decreasing neurotransmission in the DCN and output to motor centers ([Figure 1C](#F1){ref-type="fig"}). Hence, Purkinje cells are a critical relay center within cerebellar circuits and any disruption to normal Purkinje cell function would alter the function of the cerebellum overall, leading to cerebellar ataxia ([@B78]; [@B123]; [@B145]; [@B91]).

![Schematic representation of cerebellar afferents and efferents. **(A)** Normal function of Purkinje cells results in balanced excitation and inhibition in cerebellar circuitry. **(B)** Reduced excitatory input from glutamatergic climbing fibers, due to shortened length or impaired functionality, can decrease Purkinje cell firing, resulting in disinhibition of the DCN-thalamus-motor cortex circuit. **(C)** Increased excitatory input from parallel and climbing fibers, due to increased synaptic connections or increased glutamate signaling within the Purkinje cell synapse, can increase Purkinje cell firing, resulting in inhibition of the DCN-thalamus-motor cortex circuit. Excitatory inputs are highlighted in green, with inhibitory inputs highlighted in red. Black inputs can be either inhibitory or excitatory.](fnins-14-00707-g001){#F1}

The Role of Transcriptional Dysregulation in Purkinje Cell Dysfunction {#S3.SS2}
----------------------------------------------------------------------

Interestingly, disease-causing proteins linked with polyQ repeat disorders are consistently associated with transcriptional regulation, despite sharing little sequence homology (aside from the polyQ stretch) or functionality ([@B72]; [@B82]). Further, some of the disease-causing proteins are themselves transcription factors, such as expanded ataxin-7 in the case of SCA7 and TATA-binding protein (TBP) in SCA17 ([@B81]; [@B189]). Transcriptomic analysis of these SCA genes has revealed that many causative genes (21 of the 23 analyzed) share conserved transcription factor binding sites, suggesting a convergent role of transcription factors involved in the regulation of SCA genes ([@B18]). In their study, [@B18] conducted co-expression network analysis of 687 SCA patient brain samples and identified *ITPR1* to be enriched within SCA transcripts, highlighting altered calcium homeostasis as an overlapping pathogenic mechanism across SCAs. This led to a hypothesis that polyQ disease proteins yield toxic effects through dysregulation of transcription ([@B72]; [@B24]; [@B138]). Furthermore, it has been suggested that polyQ expansion can inhibit the function of histone acetyltransferases, decreasing histone acetylation and thus decreasing transcriptional activity ([@B106]; [@B39]). More recently, altered Purkinje cell transcripts have been identified as a potential pathogenic mechanism for the SCAs, with multiple transcriptional changes reported to affect the function of signaling cascades essential to Purkinje cell function.

Indeed, ATXN1 has been shown to interact with transcriptional regulators and suppress the function of genes such as retinoid and thyroid hormone receptors (SMRT), nuclear receptor co-expressor 1 (NCoR), growth factors (GFI-1) and polyglutamine binding protein 1 (PQBP1) ([@B24]; [@B121]). The pathogenesis of SCA3 has also been associated with transcriptional dysregulation, as the ataxin-3 protein is hypothesized to act as a histone binding protein, interacting and binding with transcriptional regulators such as CREB-response binding protein (CBP), TBP, histone deacetylase (HDAC) 3, HDAC6 and NCoR ([@B61]). PolyQ-expansion within the ataxin-3 protein is thought to increase the extent of histone binding, affecting histone acetylation ([@B61]). Furthermore, it has also been suggested that mutated polyQ proteins can also inhibit the function of histone acetyltransferase ([@B146]; [@B106]; [@B39]). In contrast to the findings of [@B61], polyQ-expanded ataxin-3 was found to impair histone acetyltransferase activity in SCA3 mice, resulting in histone hypoacetylation ([@B39]). Transgenic mice expressing ataxin-3 with 79 polyglutamine repeats also exhibited downregulated cerebellar expression of IP3R1, vesicular glutamate transporter type 2 (VGLUT2) and TBP-interacting protein ([@B40]). Functionally, the described transcriptional downregulation was found to alter the function or Purkinje cells in *ex vivo* cerebellar slices from ataxin-3-79Q mice.

Ataxin-7, the protein encoded by *ATXN7*, has been identified to form transcription coactivator complexes and regulate gene expression ([@B81]). PolyQ-expanded ataxin-7 has been found to colocalize with nuclear transcription factors such as CBP, TATA-binding protein-associated factor 4 (TAF4) and specificity protein 1 (SP1), forming neuronal intranuclear inclusions ([@B82]). Transcriptional dysregulation of ion channel genes has been identified in the cerebellum of SCA7 mice ([@B37]; [@B201]), suggesting this pathogenic mechanism may be shared across different SCAs or polyQ diseases.

Transcription Factors or Repressors Implicated in Purkinje Cell Dysfunction {#S3.SS3}
---------------------------------------------------------------------------

### Capicua {#S3.SS3.SSS1}

The toxicity of the ataxin- 1 protein in SCA1 mouse models has been attributed to the formation of large stable complexes with the mammalian homolog of Drosophila Capicua (CIC), a transcriptional repressor, within cerebellar Purkinje cell nuclei ([@B121]). Furthermore, this toxicity was found to be polyQ-dependent, as expression of mutant S776A polyQ-expanded ATXN1, a non-pathogenic form of the disease-associated protein, resulted in a distinct lack of CIC complexes and neuronal dysfunction in both cellular and *Drosophila* models ([@B121]). Interestingly, knockout of CIC in SCA1 mice caused improvements in motor performance ([@B67]). Whilst this finding may suggest that polyQ expansion of ATXN1 causes a reduction in CIC function, the authors hypothesized that mutant ATXN1 may cause CIC to bind more tightly to transcriptional targets, causing simultaneous hyper-repression and de-repression. [@B176] further characterized the role of the ATXN1-CIC complex in SCA1 cerebellar pathology, finding that the ATXN1-CIC complex confers a toxic gain-of-function effect in transgenic SCA1 mice, driving reduced transcription of critical genes in Purkinje cells.

More recently, [@B34] expanded on the findings of [@B176], highlighting regional differences in Purkinje cell degeneration and correlating these changes with regional patterns of transcriptional dysregulation. Interestingly, several ion channel genes, such as *KCNMA1*, *CACNA1G*, *TRPC3*, *ITPR1*, and *GRM1*, were found to be downregulated in anterior Purkinje cells isolated from SCA1 mice ([@B34]). Furthermore, this neuronal population was also found to highly express CIC ([@B34]). Collectively, the findings from [@B34] provide the first experimental evidence associating altered Purkinje cell physiology and impaired calcium homeostasis with transcriptional dysregulation in SCA1, a consequence of altered ATXN1-CIC interactions.

### RORα {#S3.SS3.SSS2}

Retinoid-related orphan receptor α (RORα) is a transcription factor that is enriched in cerebellar Purkinje cells and functionally involved in normal Purkinje cell development ([@B33]). RORα is critical for the retraction of transient Purkinje cell dendrites, facilitating development of the mature dendritic tree ([@B33]). Deletion of RORα from adult Purkinje cells resulted in regression of immature characteristics such as innervation from multiple functional climbing fibers and invasion of parallel fiber synaptic space ([@B33]). One of the first animal models of human ataxia, the staggerer mutant mouse, was later found to lack functional RORα ([@B76]). AAV-mediated knock down of RORα also lead to degeneration of Purkinje cell layer alignment, dendritic atrophy and ataxia ([@B231]), suggesting that loss of RORα function may be involved in SCA disease phenotypes.

Examination of transgenic mouse models that express pathogenic forms of ATXN1 highlighted the critical role of RORα in cerebellar development. SCA1 transgenic mice display reduced expression of RORα and reduced expression of genes regulated by RORα ([@B187]). Furthermore, SCA1 transgenic mice share phenotypic overlap with staggerer mice ([@B44]), suggesting loss of RORα function in SCA1. Interestingly, the phenotypic similarities between SCA1 mice and staggerer mice are not shared with transgenic SCA7 mice, suggesting the transcriptional changes are not caused from polyQ expansion or cerebellar dysfunction, but more likely due to a specific interaction between ATXN1 and RORα ([@B44]). In their study, [@B186] found that four genes regulated by RORα, *ITPR1*, *SLC1A6*, *PCP4(L7)* and *PCP4*, were found to be downregulated in the cerebella of both SCA1-82Q mice and stagger mice. Interestingly, mice expressing a non-pathogenic form of ataxin-1 containing 82 glutamine repeats were found to express similar levels of these genes and RORα to wild type mice ([@B187]), suggesting loss of RORα function can be attributed to the pathogenicity of expanded, mutant ataxin-1. Delayed expression of mutant ataxin-1 until maturation attenuated Purkinje cell susceptibility to neurodegeneration, turning off expression of ATXN1 resulted in a restoration of RORα expression ([@B187]). Hence, ATXN1 interacts with RORα to supress expression of RORα-regulated genes that are critical to Purkinje cell development.

In line with findings from staggerer mice and SCA1 mice, transgenic models of SCA3 also display reduced expression of RORα ([@B117]). Whilst the ataxin-1 protein is found to directly interact with RORα and forming protein complexes ([@B187]), the ataxin-3 protein does not directly bind with RORα ([@B224]), suggesting divergent underlying pathogenic mechanisms.

### PGC1α and Sirtuin 1 {#S3.SS3.SSS3}

Peroxisome proliferator activated receptor γ coactivator-1α (PGC-1α) is a transcriptional coactivator functionally involved in mitochondrial biogenesis ([@B127]; [@B223]). Deficits in expression or activation of PGC-1α have been associated with motor impairments and neurodegeneration ([@B135]). PGC-1α is highly expressed within the cerebellum and PGC-1α knockout mice develop ataxia and movement deficits ([@B136]). At the molecular level, knockout of PGC-1α results in a 30% loss of Purkinje cells and downregulation of genes involved in synaptic, structural and metabolic functions ([@B136]). PGC-1α was implicated in the regulation of parvalbumin, a calcium binding protein, highlighting a more complex role within the neuronal circuitry ([@B136]).

More recently, transcription factor binding-site analysis highlighted downregulation of genes targeted by sirtuin 1 (Sirt1) in SCA7 transgenic mice ([@B201]). Sirt1, an NAD^+^-dependent deacetylase, that has previously been associated with increased survival and reduced age-related neurodegeneration, was found to rescue transcriptional abnormalities in SCA7 mice ([@B201]). One of the identified transcriptional abnormalities was acetylation of PGC-1α. Overexpression of Sirt1 was found to rescue transcriptional abnormalities and motor deficits in SCA7 mice ([@B201]). These recent findings further highlight the role of PGC-1α in healthy Purkinje cell function and metabolism.

What Makes Cerebellar Purkinje Cells so Sensitive to Changes in Neuronal Signaling? {#S3.SS4}
-----------------------------------------------------------------------------------

The spinocerebellar ataxias have been associated with a broad suite of pathological changes to Purkinje cells, including altered cellular morphology, connectivity, physiology, cell number and the appearance of toxic protein species ([@B36]). Indeed, mutations found in SCA1, 6, 15/16, 19/22, 27, 42 have been found to produce irregular or diminished Purkinje cell signaling ([@B89]). This is contrasted with SCA2, 3, 5, 41 and 44, which have been found to enhance Purkinje cell excitability and increase signaling ([@B89]). However, it is hypothesized that the context of disease proteins may be important for toxicity, as disease proteins may alter the function of protein interactors, resulting in concomitant loss and gain-of-function effects. These concomitant effects are particularly evident in SCA1 and SCA3 ([@B66]; [@B227]). Collectively, these findings paradoxically indicate that both increased and decreased function of disease affected proteins can cause similar deficits to Purkinje cell signaling, detrimentally impacting cerebellar output and movement ([@B145]). However, it remains unclear why genetic insults lead to Purkinje cell degeneration and spinocerebellar ataxia. Here we outline three distinct properties associated with Purkinje cell function that may increase vulnerability to the pathological consequences of SCA-causing genetic mutations.

### High Metabolic Activity and Expansive Dendritic Arbor {#S3.SS4.SSS1}

In order to understand how and why Purkinje cells are so susceptible to the insults caused by in the genetic mutations underlying SCAs, it is interesting to compare Purkinje cells with other cell types within the cerebellum. Morphologically, Purkinje cells are one of the largest neuronal cell types within the cerebellum and exhibit high metabolic activity ([@B79]). Purkinje cells consume a substantial amount of ATP, due to the continuous, pacemaker firing properties ([@B68]). Purkinje cells also develop expansive dendritic arbors, a property which distinguishes them from other neuronal types within the cerebellum. Recent evidence has suggested that Purkinje cell dendritic development may be highly reliant on regulated mitochondrial fission and transport ([@B68]). Disruption of mitochondrial fission in post-mitotic Purkinje cells can lead to enlarged and impaired distribution of mitochondria throughout dendrites, reducing the energy supply to distal dendrites ([@B68]). In conditions of reduced energy supply, Purkinje cell dendrites are significantly shorter and less branched, suggesting appropriate energy supply may be required for normal development of the Purkinje cell arborization ([@B4]; [@B68]). In alignment with this hypothesis, [@B201] found metabolic dysregulation and depletion of nicotinamide adenine dinucleotide (NAD^+^) in the SCA7 mouse cerebellum. NAD^+^ depletion has also been observed in the nucleus of neurons derived from SCA7 patient induced pluripotent stem cells ([@B222]). Interestingly, increasing the availability of cellular energy, via treatment with nicotinamide riboside, ameliorated motor deficits and Purkinje cell morphological abnormalities in SCA7 transgenic mice ([@B201]). Furthermore, treatment with creatinine yielded significant therapeutic benefit in a transgenic mouse model of SCA3, improving motor performance and reducing neuronal degeneration ([@B58]). Hence, it is plausible that the high metabolic activity, large cell size and expansive dendritic arbor of Purkinje cells may leave them more vulnerable to changes in the cellular environment ([@B79]).

### Synaptic Plasticity and Glutamate-Induced Excitotoxicity {#S3.SS4.SSS2}

Structurally, Purkinje cells have substantial dendritic arbors which that receive large volumes of excitatory input ([@B79]). Climbing fiber-Purkinje cell and parallel fiber-Purkinje cell synapses undergo activity-dependent plasticity, evoking changes in Purkinje cell physiology ([@B23]; [@B101]; [@B197]; [@B91]). Increased glutamatergic input can trigger a surplus of climbing fiber-Purkinje cell synapses, with dysfunction of the protein kinase C pathway, shown to increase the number of climbing fiber-Purkinje cell synapses ([@B193]; [@B170]). In contrast, decreased glutamatergic input can reduce connectivity. Histological analysis of ataxin-1 mice revealed a reduced number of climbing fiber-Purkinje cell synapses in the distal segment of the Purkinje cell dendritic arbor ([@B8]). Shortened climbing fiber length, resulting in failure to synapse with Purkinje fiber dendrites has also been attributed to reduced Purkinje cell signaling in the pathogenesis of SCA1 ([@B59]). It is plausible that changes to climbing fiber connectivity could be a disease mechanism shared across forms of SCA.

Moreover, long-term depression (LTD) at the parallel fiber-Purkinje cell synapse has traditionally been associated with motor learning. Precise control of Ca^2+^ signaling is required for LTD to occur at the parallel fiber-Purkinje cell synapse ([@B132]). Indeed, impaired calcium signaling has been associated with impaired LTD induction at the parallel fiber-Purkinje cell synapse in ataxin-3 79Q transgenic mice ([@B40]). Collectively, these phenotypes highlight decreased inhibitory action of Purkinje cells, due to insufficient excitatory input from synapsing climbing fibers.

### Dysfunction of Purkinje Cell Physiology {#S3.SS4.SSS3}

Channels located within neuronal synapses are critical to maintaining neuronal excitability; reduced expression or functionality of channels could contribute to altered Purkinje cell excitability. There are three main types of channels; synaptic channels, which include glutamate or GABA receptors, voltage-gated ion channels which that generate ionic currents in response to membrane potential changes and ligand-gated ion channels, which are activated by secondary messengers such as neurotransmitters ([@B191]). Mutation of channels has been attributed to a range of neurological diseases including forms of ataxia, epilepsy and myotonic disorders, known collectively as channelopathies ([@B191]). In addition, changes to channel availability and localization, despite a lack of channel mutation, can also lead to alterations in intracellular trafficking and the regulation of membrane potential within the cerebellum, producing ataxia ([@B191]). Disease-associated mutations can cause toxic gain-of-function effects, dominant-negative effects and haploinsufficiency of channel function, with all three forms of mutation described in SCAs ([@B191]). There is evidence to suggest that changes to expression of channels and receptors which regulate membrane excitability may precede motor dysfunction and in cell death ([@B88]; [@B109]; [@B102]). Therefore, it is of interest to increase understanding of the basic mechanisms underlying impaired cerebellar channel function so that treatments can be developed to target these mechanisms before cerebellar circuits incur irreversible damage.

Afferent stimulation of Purkinje cells, via climbing fiber or parallel fiber synapses, is mediated by glutamatergic activation of ionotropic AMPA receptors and metabotropic glutamate receptors (mGluRs) located within the synaptic membrane, resulting in release of glutamate ([@B145]). Furthermore, activation of mGluRs can increase intracellular calcium signaling via activation of the protein kinase C (PKC) pathway, which increases calcium concentrations through cation channels, such as the transient receptor potential type 3 (TRPC3), and the inositol 1,4,5- trisphosphate receptor (IP3R1)([@B17]; [@B132]; [@B204]; [@B211]).

Impaired regulation of calcium signaling within cerebellar Purkinje cells is one of the most characterized disease mechanisms underlying spinocerebellar ataxias. Genetic mutation of voltage-gated calcium channels has been identified in both SCA6 and SCA42, however mutations in downstream calcium signaling molecules, such as IP3R, are also prolific within SCA subtypes. Furthermore, mutation of voltage-gated potassium or sodium channels can also contribute to altered Purkinje cell excitability. Whilst AMPA receptor function remains relatively spared in SCAs, loss of mGluR function, or downstream glutamate signaling, has been identified in SCA5 and SCA44. Ultimately, each of these disease mechanisms alter synaptic neurotransmission, leading to progressive cerebellar dysfunction and pervasive loss of Purkinje cells resulting in SCA motor phenotypes ([@B91]).

#### Homeostatic control of calcium signaling {#S3.SS4.SSS3.Px1}

Homeostatic control of intracellular calcium release is a functionally important cellular mechanism, as calcium ions (Ca^2+^) can act as an intracellular messenger initiating other processes such as synaptic neurotransmission and transcriptional regulation ([@B17]; [@B204]). Furthermore, appropriate calcium concentrations are required to facilitate long term potentiation (LTP) and long term depression (LTD) within the cerebellum ([@B132]). Excessive intracellular calcium can induce toxicity and detrimentally impact on neuronal cell survival ([@B108]).

Increased Ca^2+^ influx triggers activation of the PKC signaling pathway ([@B17]). Activation of mGluRs via binding with glutamate, activates a signaling cascade, ending with release of Ca^2+^ from the endoplasmic reticulum via activation of IP3R1 ([Figure 2](#F2){ref-type="fig"}). This initial release of Ca^2+^ into the cytosol can be further amplified via activation of ryanodine receptors (RyanR), an intracellular Ca^2+^ release channel ([@B17]; [@B132]; [@B204]). Depletion of endoplasmic reticulum calcium stores triggers translocation of stromal interaction molecule 1 (STIM1), an endoplasmic reticulum calcium sensor, to the peripheral endoplasmic reticulum cisternae, triggering activation of TRPC3 channels ([@B170]). It is well regarded that disrupted calcium signaling may initiate cellular processes, which eventuate in cerebellar Purkinje cell death ([@B108]; [@B138]; [@B23]; [@B85]; [@B170]).

![Many forms of spinocerebellar ataxia are attributed to mutations in intracellular calcium signaling, glutamate release or the PKC pathway, which form multiple positive feedback loops. Disruption of calcium and glutamate signaling is hypothesized to initiate Purkinje cell dysfunction, resulting in ataxia and eventual cell death. Diseases indicated in red are reported to have dysfunction of this component of the signaling pathway.](fnins-14-00707-g002){#F2}

#### Mutation of voltage-gated calcium channels in SCA diseases {#S3.SS4.SSS3.Px2}

Voltage-gated calcium channels regulate the influx of Ca^2+^ into neurons during membrane depolarization. As such, voltage-gated calcium channels modulate neuronal excitability and can trigger calcium-dependent processes including release of neurotransmitters, synaptic plasticity and gene transcription ([@B28]). High-voltage P/Q-type (Cav2.1), N-type (Cav2.2) and R-type (Cav2.3) channels are considered as the primary driver of evoked synaptic transmission ([@B28]). Functionally, Cav2.1 channels are critical to the regulation of spiking properties and contribute to calcium spikes triggered by increased activity of cerebellar climbing fibers. In contrast, T-type voltage-gated calcium channels (Cav3.1, Cav3.2 and Cav3.3) are activated by lower voltage thresholds and exhibit a hyperpolarised range of activation and inactivation, making them ideally suited to regulate neuronal activity ([@B234]; [@B77]). T-type channels are typically inactivated, however postsynaptic inhibitory events can recover T-type channels from inactivation, facilitating "rebound bursting" ([@B234]; [@B77]). Voltage-gated calcium channels have also been found to functionally interact with large conductance calcium-activated potassium (BK) channels, providing additional modulation of neuronal excitability through BK channel activity ([@B234]).

The presence of a mutation in the *CACNA1A* gene, which encodes the α1A-subunit of voltage-gated P/Q-type calcium channels (Cav2.1), results in an array of neurological disorders including SCA6, episodic ataxia type 2 and familial hemiplegic migraine type 1 ([@B235]; [@B143]; [@B205]). Each of the neurological disorders is associated with a different *CACNA1A* mutation, suggesting differential effects on Ca^2+^ signaling ([@B235]). Initially, SCA6 pathogenesis was thought to stem from dysfunction of the voltage gated calcium channel Cav2.1, which is encoded by *CACNA1A* gene ([@B235]; [@B143]; [@B205]). However, experimental animal models expressing mutant *CACNA1A* failed to consistently yield deficits in Cav2.1 function ([@B143]; [@B205]). More recently, *CACNA1A* was identified as a biscistronic gene, encoding both the α1A subunit of the P/Q type voltage-gated calcium channel Cav2.1 and α1ACT, a transcription factor which shares sequence homology with the cytoplasmic c-terminal of the α1A subunit ([@B143]; [@B205]). Interestingly, the polyQ expansion is present within both independently translated proteins. Functionally, α1ACT is involved in cerebellar development and enhances expression of genes essential for Purkinje cell survival, such as GRN, PMCA2 and BTG1 ([@B55], [@B56]). PolyQ-expanded α1ACT exhibits reduced transcription factor function and produces nuclear toxicity, resulting in ataxia and neuronal death, driving SCA6 pathology ([@B55], [@B56]; [@B11]; [@B160]).

Recently, genetic sequencing lead to the identification of a single point mutation in the *CACNA1G* gene in ten SCA42 families ([@B43]; [@B147]; [@B112]; [@B152]; [@B77]). This mutation, which causes an arginine to histidine change, alters the voltage-sensing region of T-type voltage-gated calcium channel Cav3.1 ([@B77]). Functionally, this mutation is thought to impair Purkinje cell "rebound bursting," requiring higher voltage thresholds to elicit depolarization of Purkinje cells ([@B77]). To further confirm if this point mutation is the phenotypic driver of SCA42 pathology, a transgenic mouse model (Cacna1g-Arg1723His) has been generated ([@B77]). Cacna1g-Arg1723His mice recapitulated many pathological hallmarks of human SCA42, including early adulthood onset of ataxia and cerebellar atrophy ([@B77]). Interestingly, Cacna1g-Arg1723His mice did not display any direct impairments to Purkinje cell signaling. Nevertheless, the firing of inferior olivary neurons was found to be altered, enhancing activity of climbing fiber-Purkinje cell synapse and thus Purkinje cell excitability ([@B77]). Interestingly, Cacna1g-Arg1723His mice share phenotypic similarities with Cav3.1 knockout mice ([@B140]), suggesting loss of Cav3.1 function in SCA42 ([@B77]).

#### Dysfunction of calcium signaling within the protein kinase C pathway {#S3.SS4.SSS3.Px3}

Spinocerebellar ataxia type 14 is caused by mutation to of the *PRKCG* gene ([@B20]; [@B148]), which encodes the PKCγ isoform of the PKC subfamily (PKCγ) and is activated by binding with the secondary messenger DAG, in the presence of phosphatidylserine ([@B17]; [@B179]). Currently, over 40 different mutations in *PRKCG* have been attributed to SCA14, with some mutations causing a loss of PKCγ function, whilst other mutations enhance PKCγ function ([@B212]; [@B1]; [@B193]; [@B103]). Increased intracellular levels of Ca^2+^ stimulate PKCγ to translocate from the cytosol to the plasma membrane ([@B17]; [@B211]; [@B170]). PKCγ is expressed throughout the central nervous system and is specifically localized to neurons ([@B179]). In the cerebellum, PKCγ is highly expressed within Purkinje cells and is implicated in the normal development of climbing fiber input from the inferior olive ([@B30]; [@B107]; [@B193]). It is likely that PKCγ may be critical to normal Purkinje cell function and hence may be an important therapeutic target. Several SCA14 mutations have been found to enhance the intrinsic activity of PKCγ ([@B1]), leading to decreased binding with DAG and decreased inhibition of extracellular Ca^2+^ entry through TRPC3 receptors ([@B211]). Absence of PKCγ-mediated control of TRPC3 channel activity causes prolonged, aberrant increases in intracellular Ca^2+^ signaling in Purkinje cells ([@B211]). Transgenic mice expressing an S361G mutation in PKCγ display severe loss of PKCγ function, evidenced by inhibited dendrite development, Purkinje cell degeneration and ataxia ([@B103]), aligning with cerebellar deficits found in human SCA14 patients.

Interestingly, there is considerable experimental evidence to suggest abnormal IP3R1 function, a downstream signaling protein found within the PKCγ pathway, in the pathogenesis of many spinocerebellar ataxias and other neurodegenerative diseases including Huntington's disease and Alzheimer's disease ([@B203]; [@B170]). IP3Rs are intracellular inositol triphosphate-3 (IP3) channels which that release stored calcium from the endoplasmic reticulum ([@B17]; [@B132]; [@B204]). IP3Rs, in addition to other intracellular calcium channels such as RyanRs, are critical to maintaining free calcium concentrations within the cytoplasm ([@B17]; [@B132]; [@B204]). IP3Rs are specifically expressed in the central nervous system, with high expression in cerebellar Purkinje cells, the basal ganglia and thalamus ([@B132]; [@B203]). Furthermore, IP3R1 is the key receptor type responsible for regulating climbing fiber and parallel fiber inputs to Purkinje cell dendrites, linking synaptic signaling with LTP and LTD ([@B132]; [@B91]). IP3R1, via binding with IP3, mediates the spaciotemporal activity of calcium oscillations which are required for the induction of LTD ([@B132]; [@B91]).

Homozygous *ITPR1* knockout mice, which are deficient in cytosolic IP3-mediated Ca^2+^ release, display diminished LTD, severe ataxia and tonic-clonic seizures, resulting in death by weaning age ([@B139]). Mutation of the *ITPR1* gene, which encodes IP3R1, results in both SCA15/16 and SCA29 ([@B200]; [@B208]). Most causes of SCA15 are attributed to haploinsufficiency of IP3R1 and suppressed calcium signaling, however one mutation (P1059L) has been found to increase IP3 affinity with no effect on calcium signaling ([@B5]). In contrast, eleven missense mutations in *ITPR1* have been associated with SCA29, however the functional consequences of the mutations are relatively unknown ([@B5]). Most SCA29 mutations induce dominant-negative effects, abolishing IP3R1 activity or carbonic anhydrase-related protein VIII (CAR8)-mediated regulation of IP3R1, resulting in decreased calcium release, whilst the R36C mutation induces a toxic gain-of-function, enhancing calcium release ([@B5]).

In calcium imaging and electrophysiology experiments, [@B32] evidenced increased sensitivity of IP3R1 channels and potentiation of IP3R-mediated calcium release in MJD/SCA3 patient fibroblasts compared with healthy controls. This study went further to show preferential binding between full length IP3R1 and expanded ataxin-3 proteins (77Q and 127Q), but not wild type ataxin-3 in both cells and mice modeling SCA3. This finding was also replicated *in vivo*, with anti-ataxin 3 monoclonal antibodies precipitating IP3R1 from cortical lysates obtained from SCA3-YAC-84Q transgenic mice, but not wild type controls ([@B32]). Collectively, these findings suggest that mutant ataxin-3 interacts with IP3R1, resulting in elevated calcium signaling. Similarly, [@B131] found that pathological forms of the ataxin-2 protein, but not wild type ataxin-2, also interact with the cytosolic C-terminal region of IP3R1s, consequently increasing IP3R1 activation and IP3R1-mediated Ca^2+^ responses in cultured Purkinje cells ([@B131]). Furthermore, investigation of IP3R1-mediated Ca^2+^ signals in cultured Purkinje cells revealed that inhibition of RyanR1 could attenuate calcium signals and protect against glutamate-induced toxicity ([@B131]). *In vivo* experimentation also revealed amelioration of disease phenotypes in ataxin-3 and ataxin-2 transgenic mice following chronic treatment with dantrolene, a clinically approved compound used for the treatment of hyperthermia and muscle spasticity ([@B32]; [@B131]). Due to the similarities in binding, it has been hypothesized that the polyQ tract within expanded ataxin-2 and ataxin-3 specifically binds to IP3R1, producing toxic enhancement of IP3R1 function ([@B32]; [@B131]). Treatments that target or modulate IP3R1s may be beneficial to multiple SCAs.

Many proteins involved in maintaining calcium homeostasis have been found to be downregulated in animal models of SCA1, including IP3R1, CAR8, Cav3.1, TRPC3 and sarco-endoplasmic reticulum Ca^2+^ ATPase 2 ([@B129]; [@B186]; [@B170]). Furthermore, SCA1 transgenic mice also displayed reduced expression of calcium binding proteins, including calbindin and parvalbumin ([@B217]). It is hypothesized that downregulation of calbindin and parvalbumin may impair the ability of Purkinje cells to appropriately buffer excessive calcium, which is further exacerbated by reductions in calcium binding proteins ([@B23]). Accordingly, suppression of calbindin in SCA1 mice enhanced the severity of SCA1 phenotypes, worsening motor performance and neuronal loss ([@B216]). In contrast, knockout of ASIC1a, acid-sensing channel isoform 1a, which transmits inward calcium currents upon activation, improved motor performance and increased intensity of calbindin and parvalbumin staining ([@B215]). Collectively, the findings of Vig and colleagues suggest that in SCA1 transgenic mice, intracellular calcium handling may be impaired due to reduced expression of the calbindin protein, consequently increasing the sensitivity of Purkinje cells to altered calcium homeostasis. Similar findings were also reported in SCA7-92Q mice, with immunohistochemical examination revealing reduced expression of Cav3.1 and calbindin in the posterior cerebellum ([@B201]). This finding is of particular interest as altered calcium homeostasis had not previously been associated with SCA7, providing further evidence of disrupted calcium homeostasis as a central pathogenic mechanism across SCAs.

### Dysfunction of Other Ionotropic Channels {#S3.SS4.SSS4}

SCA5 and SCA27 share similar pathophysiology, with both diseases resulting in reduced Purkinje cell excitability due to reduced expression or activation of voltage-gated sodium channels. Reduced excitability of Purkinje cells could result in decreased signaling at the Purkinje cell-DCN synapse, reducing excitation of DCN projections to motor centers ([@B36]). Mice deficient in beta-III spectrin, encoded by the gene *SPTBN2*, mutated in SCA5 patients ([@B95]), displayed decreased Purkinje cell firing and worsening with disease progression ([@B165]). Electrophysiological slice recordings from beta-III spectrin knockout mice demonstrated reduced spontaneous firing rates, reduced total sodium current and reduced resurgent sodium current ([@B165]). Mutation of beta-III spectrin has been found to affect localization of membrane bound protein in dendrites and cell bodies, exerting a dominant negative effect on sodium channel complexes.

The pathogenesis of SCA27 has been attributed to mutation of fibroblast growth factor 14 (*FGF14*), which binds with voltage-gated sodium channels and overall modulating neuronal excitability ([@B230]). *FGF14* knock out mice showed failed spontaneous firing, degraded responsiveness to depolarizing current, loss of Nav1.6 within Purkinje cells and ataxia, aligning with the disease features present in SCA27 patients ([@B119]). Furthermore, cultured neurons expressing mutated *FGF14* displayed decreased sodium channel currents and neuronal excitability, suggesting a dominant-negative effect ([@B119]; [@B192]). It is hypothesized that mutant FGF14 may disrupt the function of wild-type FGF14 protein which acts to stabilize sodium channel expression, thus leading to altered expression of voltage-gated sodium channels ([@B119]; [@B192]). Furthermore, FGF14 was also found to regulate voltage-gated calcium channels, Cav2.1 and Cav2.2 ([@B230]). Expression of pathological FGF14 in cerebellar granule cells exerted a dominant-negative effect on Cav2.1 and Cav2.2, reducing Ca^2+^ influx and diminishing excitatory postsynaptic currents at the granule cell-Purkinje cell synapse ([@B230]). Evidence suggests that FGF14 can regulate multiple ionic currents, therefore the pathogenesis of SCA27 may be mediated by decreased function of both voltage-gated sodium channel and voltage-gated calcium channels, leading to reduced output of Purkinje cells ([@B230]).

Spinocerebellar ataxia type 13 (SCA13) is caused by loss of Kv3.3 function ([@B226]; [@B63]). Kv3.3 is functionally involved in depolarizing both somatic sodium spikes and dendritic calcium spikes within Purkinje cells, with some expression in granule cells and DCN neurons. Therefore, loss of voltage-gated potassium channel function leads to neuronal hyperexcitability and impaired calcium homeostasis ([@B99]; [@B23]). Expression of mutant *KCNC3* (R424H) resulted in disrupted dendritic development, altered Purkinje cell spiking and cell death in cerebellar cultures ([@B99]). Interestingly, SCA13 mutations are capable of both decreasing and increasing Kv3.3 activity ([@B226]; [@B63]). Furthermore, exome sequencing of two SCA19/22 families lead to the identification of a missense mutation in *KCND3*, which encodes the voltage-gated potassium channel Kv4.3 ([@B57]; [@B124]). Mutation of *KCND3* causes a toxic loss-of-function, as Kv4.3 is retained within the endoplasmic reticulum instead of localizing to the plasma membrane, resulting in LTP impairments at the Purkinje cell synapse ([@B57]; [@B124]).

Emerging evidence suggests that dysfunction of calcium-activated potassium channels can be attributed to increased intrinsic excitability of Purkinje cells in SCA1, SCA2 and SCA7. In ataxin-1 82Q-expressing mice, expression of large-conductance calcium-activated potassium (BK) channels and G-protein coupled inwardly rectifying potassium (GIRK1) channels is decreased with disease progression. Furthermore, [@B48] observed a correlation between decreased Purkinje cell firing and increased conduction of K^+^. Virally mediated overexpression of BK channels improved motor performance and rescued dendritic degeneration in SCA1 mice ([@B48]). More recently, [@B201] observed irregular spiking patterns and reduced capacitance in Purkinje cells of the posterior cerebellum in transgenic mice expressing ataxin-7 with a polyglutamine length of 92. The authors hypothesized that this neurophysiological abnormality was due to dysfunction of calcium activated potassium channels, and indeed found reduced expression of BK channels within the cerebellum ([@B201]). Furthermore, viral overexpression of BK transcripts improved the regularity of Purkinje cell spiking [@B201], highlighting similarities between SCA1 and SCA7.

The pathogenesis of SCA1 may also be attributed to altered potassium channel function, leading to imbalance in the depolarizing and hyperpolarizing currents and consequently altered neuronal spiking ([@B23]). Hence, impairments in Purkinje cell firing in SCA1 may be underscored by impaired BK channel function. Similarly, SCA2 mice expressing ataxin-2-128Q within Purkinje cells failed to maintain neuron spiking due to a reduction in transcript levels of *KCNMA1* ([@B47]). Therefore, dysfunction of voltage-gated potassium channel may contribute to irregular Purkinje cell spiking in animal models of SCA.

### Glutamate Signaling Within the Cerebellum {#S3.SS4.SSS5}

Glutamate is the most abundant neurotransmitter within the mammalian brain. Under normal conditions, glutamate can trigger transient increases in calcium levels within Purkinje cells via activation of mGluRs and ionotropic, such as AMPA receptors and NMDA receptors ([@B167]; [@B109]; [@B227]). Historically, Purkinje cells were thought to lack NMDA receptors, relying on other glutamatergic receptors to modulate glutamate signaling ([@B164]; [@B133]). However, the presence of NMDA receptors was confirmed at the climbing fiber-Purkinje cell synapse ([@B166], [@B167]), suggesting a role of NMDA receptors within cerebellar circuitry.

Binding of glutamate to mGluRs at the Purkinje cell synapse activates a complex cascade, the PKC pathway, which increases intracellular release of calcium. In contrast, activation of AMPA or NMDA receptors triggers membrane depolarization, activating voltage-gated calcium channels and cytoplasmic Ca^2+^ influx ([@B108]). Activation of mGluR, AMPA or NMDA receptor evokes a transient increase in cytosolic calcium levels, eliciting excitation of Purkinje cells ([@B108]).

Metabotropic glutamate receptor type 1 (mGluR1), encoded by *GRM1* gene, is one of the most highly expressed receptor types within the mammalian central nervous system, with particularly high abundance in Purkinje cells ([@B227]). Neuronal excitability is modulated by mGluRs, which yield slow excitatory post-synaptic currents, and excitatory amino acid transporters (EAATs), which transport glutamate ([@B168]). Glutamate re-uptake from the Purkinje cell presynaptic cleft is critical for precise signaling and is modulated by EAAT1 (GLAST), EAAT2 (GLT1) and EAAT4 ([@B168]; [@B23]). Moreover, EAAT4 modulates mGluR1-mediated events at the parallel and climbing fiber synapses, influencing plasticity ([@B168]). A reduction in the expression of EAATs or mGluRs would result in prolonged excitatory synaptic transmission, as glutamate is not being effectively removed from the synapse ([@B168]). Furthermore, increased activation of Purkinje cells would in turn, increase inhibitory inputs received by the DCN, resulting in defective cerebellar output ([@B168]). Deletion of GRM1 has been shown to cause an ataxic phenotype ([@B42]), whilst restoration of normal mGluR1 expressing in Purkinje cells can rescue motor impairments ([@B93]; [@B151]). This evidence highlights the critical role of mGluR1 signaling in Purkinje cell development and function.

### Evidence for Disrupted Glutamate Signaling in SCAs {#S3.SS4.SSS6}

Recently, missense mutation of *GRM1* was identified in three SCA44 families ([@B227]). Expression of mutant mGluR1 was found to dramatically enhance mGluR1 activity, evoking a toxic gain-of-function and producing excitotoxicity within Purkinje cells via a positive-feedback loop ([@B227]). Increased excitatory input triggers increased release of glutamate and thus mGluR1 activation, which in turn produces increased in intracellular calcium levels. However, increased intracellular calcium levels act to potentiate mGluR1-mediated signals, thus promoting increased downstream calcium signaling ([@B227]). Whilst mutation of *GRM1* is relatively rare, dysfunction of mGluR1 and other downstream components of the mGluR1signalling pathway have previously been associated with spinocerebellar ataxias. The deleterious impacts of reduced mGluR1 function are highlighted in transgenic knockout models, which evidence functional deficits such as altered LTD, abnormal Purkinje cell innervation and ataxia ([@B2]; [@B93]; [@B175]).

Impairments in mGluR1 function has also been observed in animal models of human spinocerebellar ataxia, including SCA1, SCA2 and SCA3 ([@B154]; [@B170]). In SCA3, mGluR1 is mislocalized, resulting in reduced synaptic expression and disruption of normal mGluR1 signaling ([@B117]). In contrast, SCA1 and SCA2 has been associated with mGluR1 hyperactivity, a consequence of prolonged elevations in Ca^2+^ concentrations ([@B169]; [@B144]). It is likely that increases in glutamate load and reduced calcium buffering capacity within Purkinje cells may combine to form a deleterious positive feedback loop, further propagating mGluR and calcium signaling disturbances, consequently driving Purkinje cell dysfunction ([@B145], [@B144]). Recent evidence has highlighted that changes to mGluR signaling and reduced amplitude of mGluR-mediated excitatory post-synaptic potentials may precede degeneration of Purkinje cell dendrites ([@B163]). Impairment of mGluR-mediated signaling may also impair LTD of Purkinje cell-parallel fiber synapses, resulting in altered motor learning and motor deficits ([@B163]; [@B91])

Transient receptor potential type 3 channels are functionally involved in mGluR1-mediated slow post-synaptic currents and found within the same protein complex as mGluR1, localizing to Purkinje cell soma and dendrites ([@B12]; [@B170]). Furthermore, TRPC3 channels functionally interact with mGluR1s to induce LTD and mediate extracellular Ca^2+^ entry ([@B211]; [@B14]). Activity of TRPC3 is negatively regulated by phosphorylation of PKCγ; loss of PKCγ-mediated inhibition may enhance glutamate and calcium signaling ([@B211]; [@B12]). Transgenic mice expressing a missense mutation in *TRPC3*, moonwalker mice, display enhanced TRPC3 function resulting in ataxic gait and Purkinje cell loss ([@B14]). Recently, a point mutation in *TRPC3* was implicated in an adult-onset form of ataxia ([@B66]), now classified as SCA41. This mutation was found to infer a toxic gain-of-function, increasing Purkinje cell degeneration and sharing phenotypic similarities with moonwalker mice ([@B13]). It was hypothesized that this toxic gain-of-function mutation causes calcium overload, resulting in Purkinje cell dysfunction and degeneration ([@B12]).

As previously described, SCA5 has been found to be caused by mutation of the *SPTBN2* gene, which encodes the beta-III spectrin protein ([@B95]). Beta-III spectrin is functionally involved in stabilizing EAAT4 at the Purkinje cell membrane ([@B95]; [@B165]). More recently, mutation of beta-III spectrin was also found to interact with the α-subunit of mGluR1 (mGluR1α) causing mislocalization of mGluR1α in Purkinje cell dendritic spines, decreased responsiveness of postsynaptic mGluR1 and impaired mGluR1-mediated LTP ([@B6]). Therefore, loss of beta-II spectrin function in SCA5 likely results in excessive glutamate presence within the synapse and glutamate toxicity in the postsynaptic neuron ([@B23]). Furthermore, reduced EAAT-4 expression has also been observed in the cerebellum of transgenic SCA1 mice ([@B129]; [@B186]).

Despite different underlying pathogenic mechanisms initiating neuronal dysfunction and degeneration, increased exposure to glutamate has been shown accentuate toxicity. Application of the mGluR1/5 agonist, DHPG, resulted in increased amplitude of calcium transients in cultured Purkinje cells expressing pathogenic ataxin-2 and ataxin-3 ([@B32]; [@B131]). Furthermore, direct application of glutamate was found to increase neuronal death and increase production of toxic protein fragments in cellular models of SCA2 and SCA3 ([@B131]; [@B115]). Therefore, increased glutamate exposure may act to further enhance the toxic effect of other disease mechanisms in models of SCA.

What Makes Cerebellar Purkinje Cells so Sensitive to Changes in Calcium and Glutamate Signaling? {#S3.SS5}
------------------------------------------------------------------------------------------------

Under normal conditions, transient increases in intracellular calcium levels are well tolerated, however more prolonged increases can be damaging ([@B108]). Purkinje cells maintain calcium homeostasis via expression of calcium channels, calcium sensors, calcium buffers and calcium-sensitive kinases ([@B132]; [@B108]). It is hypothesized that as Purkinje cells progressively degenerate, their ability to regulate intracellular calcium homeostasis is reduced ([@B145]). There are two specific mechanisms by which Purkinje cells manage supraphysiological calcium levels; calcium binding proteins and mitochondrial up-take of excess calcium ions ([@B132]). There is considerable evidence to suggest one or both mechanisms may be disrupted in transgenic animal models and human SCA patients ([@B108]; [@B216]; [@B23]; [@B116]; [@B170]).

Firstly, excess intracellular Ca^2+^ can be taken up calcium binding proteins calbindin and parvalbumin ([@B132]; [@B9]). These calcium binding proteins are found exclusively within GABAergic interneurons, with calbindin expressed within Purkinje cells, whilst parvalbumin is expressed within basket cells, stellate cells and Golgi cells ([@B9]). Calcium binding proteins are enriched within Purkinje cells and act as the first line of defense for calcium buffering ([@B132]; [@B9]; [@B108]). It is hypothesized that the relatively high expression levels of calcium binding proteins within Purkinje cells may accommodate large Ca^2+^ influxes that occur as a result of repetitive neuronal spiking and the increased metabolic load of Purkinje cells ([@B23]). The important neuroprotective role of endogenous calcium binding proteins are highlighted in transgenic calbindin knockout mice, which present with mild ataxic symptoms and impaired Purkinje cell physiology ([@B3]; [@B9]; [@B108]; [@B23]). Furthermore, knockout of both calbindin and parvalbumin in ataxin-1-expressing mice resulted in an exacerbated the phenotype, producing severe ataxia and altered Purkinje cell morphology ([@B216]).

As a second line of defense, some excess Ca^2+^ can be stored by Purkinje cell mitochondria ([@B108]). However, mitochondria can quickly become overloaded, initiating activation of calcium sensitive enzymes including phosphatases and kinases, potentially altering gene transcription and proteases such as calpains, which can cleave and degrade cellular substrates ([@B108]). Increased activation of nitric oxide synthase in turn increases production of nitric oxide, which can trigger DNA damage and mitochondrial dysfunction ([@B108]). Interestingly, mutation of *AFG3L2*, which encodes the m-AAA subunit of the mitochondrial metalloprotease AFG3L2 (ATPase family gene 3-like 2) has been found to underlie SCA28 ([@B52]; [@B4]; [@B116]). Functionally, this mutation causes a dominant negative effect on of m-AAA protease activity ([@B52]), resulting in accumulation of mitochondrial Ca^2+^ uniporter expression ([@B116]). Post mortem analysis of SCA28 patient brain tissue has revealed mitochondrial swelling within Purkinje cells ([@B52]; [@B4]).

It is possible that when Purkinje cells are exposed to prolonged supraphysiological levels of intracellular calcium, SCA phenotypes may be caused by one convergent SCA pathology, regardless of the underlying genetic mutation ([@B144]). This hypothesis, the mGluR-Ca^2+^ of SCA pathogenesis, suggests that the ultimate degeneration and loss of Purkinje cells is mediated by two potent positive feedback mechanisms ([@B145]; [Figure 3](#F3){ref-type="fig"}). Firstly, [@B10] demonstrated that increased intracellular Ca^2+^ results in potentiation of mGluR-mediated signals. Hence, elevated levels of Ca^2+^ within Purkinje cells activates a positive feedback loop, producing further increases in intracellular Ca^2+^ via increased TRPC3 currents and IP3R1-mediated release ([@B132]; [@B204]; [@B145]). In addition, the indirect interaction between IP3R1 activity and Ca^2+^ is governed by a bell-shaped curve, whereby both low and high concentrations of intracellular calcium elicit potentiation of IP3R1-mediated Ca^2+^ release, whilst moderate intracellular Ca^2+^ concentrations inhibit IP3R1 activity ([@B19]; [@B64]; [@B132]). Experimental evidence gathered from SCA2 transgenic mice provides support for this hypothesis, demonstrating SCA2 phenotypes are exacerbated by positive feedback mechanism, linking elevations in basal calcium concentrations with increased mGluR1 signaling and IPR31-mediated release of intracellular calcium ([@B144]). As IP3R1 is uniquely expressed within Purkinje cells, it is plausible that these distinct positive feedback loops may increase the vulnerability of Purkinje cells to calcium overload, ultimately enhancing influx of calcium to the intracellular space ([@B132]; [@B145]). Furthermore, this mechanism of rising calcium overload could potentially explain the varied progression of different forms of SCA ([@B145]). For example, SCA1, 2 and 3 are widely regarded to pertain impaired mGluR1 or IP3R1 function ([@B129]; [@B32]; [@B131]) and are additionally, considered to be more severe forms of disease ([@B163]). Further insight into calcium overload and the mGluR-Ca^2+^ excitotoxicity hypothesis of SCA may reveal a positive correlation between disease severity and dysfunction of mGluR and/or IP3R1.

![The mGluR-Ca^2+^ hypothesis of SCA pathogenesis. Increases in glutamatergic signaling consequently increase intracellular calcium concentrations via two distinct pathways. Firstly, glutamate binds with AMPA and NMDA receptors, eliciting neuronal depolarization and influx of calcium. Secondly, glutamate binds with mGluR1 receptors, causing activation of the PKCγ pathway, which increases intracellular calcium concentrations via activation of IP3R1 and TRPC3.](fnins-14-00707-g003){#F3}

Treatments Aimed at Rectifying Impaired Cerebellar Physiology {#S4}
=============================================================

Currently, treatment of the SCAs is predominately aimed at alleviating disease symptoms. Evidence gathered from transgenic mouse models of SCA suggest that pathogenic changes in Purkinje cell neurophysiology are correlated with the onset of motor deficits and early stages of neuronal loss ([@B23]). Therefore, it is hypothesized that electrophysiological dysfunction may be an early contributor to disease pathogenesis and that treatments which target these early disease states may aid to slow the progression of motor dysfunction and neurodegeneration ([@B23]). Therapeutic approaches that aim to correct impaired modulation of ion release or improve glutamate re-uptake may improve synaptic physiology in SCAs ([@B23]).

Treatments Aimed at Rectifying Transcriptional Dysregulation {#S4.SS1}
------------------------------------------------------------

Transcriptional regulation is mediated by two enzymes, histone deacetylase (HDAC) and histone acetyltransferase (HAT). HDACs act to remove acetyl groups from ε-N-acetyl lysine, causing chromatin remodeling and repression of transcription ([@B24]; [@B75]). In contrast, HAT adds acetyl groups opening chromatin architecture and increasing transcription ([@B24]). Many SCA-associated genes have been found to confer haploinsufficiency or loss-of-function effects, these include *ATXN7* (SCA7), *ITPR1* (SCA15/16, SCA29), *KCND3* (SCA 19/22), *FGF14* (SCA27), *AFG3L2* (SCA28) and *CACNA1G* (SCA42). Considering this, treatments that increase gene transcription may be of therapeutic benefit in the SCAs. One treatment approach is to inhibit the activity HDAC, resulting in increased histone acetylation, chromatin relaxation and increased transcription, ameliorating dysfunction caused by loss-of-function mutations.

In contrast, many SCAs are characterized by gain-of-function gene mutations and it is hypothesized that mutant, expanded polyQ proteins may result in loss of HAT function and abnormally interaction with HDACs ([@B24]), causing transcriptional dysregulation. Therefore, treatments that increase transcription may yield increased toxicity due to increased expression of pathogenic disease proteins. However, many SCAs that yield toxic enhancements in gene function, also yield concomitant loss of interacting partner function. For example, mutant ATXN1 is generally considered to possess enhanced function, however functionality of the transcriptional co-repressor CIC is decreased when interacting with mutant ATXN1 ([@B176]), resulting in downregulation of many key ion channel channels that are critical for maintaining Purkinje cell function ([@B34]). Hence, it can be argued that SCA1 confers concomitant gain and loss of function effects ([@B121]). Thus, whilst HDAC inhibition may increase translation of mutant polyQ proteins, this negative effect may be outweighed by the neuroprotective benefit of increasing expression of genes that have previously been shown to be downregulated, leading to impaired function of Purkinje cells. In these SCAs, benefit may be enhanced via treatment with HDAC inhibitors that also aid clearance of toxic protein species ([@B24]). In our laboratory, we have found treatment with HDAC inhibitors to yield protective benefits in models of SCA3, rectifying histone acetylation and aiding the clearance of toxic ataxin-3 species (unpublished).

Previous studies have reported that treatment with HDAC inhibitors can have neuroprotective effects for the treatment of polyglutamine repeat diseases ([@B62]; [@B146]; [@B24]; [@B106]; [@B122]; [@B37], [@B38]). Sodium butyrate, the sodium salt of the short chain fatty acid butyric acid, is a class I and IIa HDAC inhibitor produced naturally during digestion by gut microbiota ([@B29]). Sodium butyrate has been found to improve movement phenotypes and inhibit HDAC enzyme activity in models of Huntington's Disease and spinal and bulbar muscular atrophy ([@B62]; [@B146]). In a transgenic mouse model of SCA3, chronic treatment with sodium butyrate ameliorated histone hypoacetylation and reduced movement deficits ([@B38]). Furthermore, sodium butyrate decreased neuronal death in primary neuronal cultures derived from ataxin-7 (100Q) expressing rats ([@B122]). Sodium valproate (valproic acid or divalproex sodium), a class I and IIa HDAC inhibitor, has also been found to yield improvements in transcriptional dysregulation and improve proteinopathy in animal models of SCA3 ([@B232]; [@B130]; [@B221]; [@B220]). Furthermore, a Phase I/II clinical trial of valproic acid in SCA3 patients reported improvements to motor function but also minor adverse effects ([@B125]). Valproic acid has also been found to be beneficial for patients with episodic ataxia type 2, caused by mutation in the CACNA1A gene ([@B184]).

Activation of sirtuin 1 (SIRT1), a class III NAD^+^-dependent histone deacetylase ([@B24]), was recently found to yield neuroprotective effects in a transgenic mouse model of SCA7 through transactivation of calcium regulatory genes ([@B201]). Treatment with the compound nicotinamide riboside increased NAD^+^ availability, increasing the activity of SIRT1 and transcription of SIRT1-mediated genes, consequently improving calcium homeostasis and regularity of spiking in cerebellar Purkinje cells in transgenic mice expressing ataxin-7 with 92 glutamines ([@B201]).

Treatments Aimed at Correcting Voltage-Gated Ion Channel Function {#S4.SS2}
-----------------------------------------------------------------

It is hypothesized that treatments that restore normal Purkinje cell pacemaker firing and reduce activation of calcium-dependent proteases and cell death processes could slow the progression of neurodegeneration ([@B23]). Previously, compounds that have been found to modulate Purkinje cell excitability and reduce hyperexcitability have provided neuroprotective benefits in models of SCA ([@B23]).

The intrinsic pacemaker firing of Purkinje cell is vital to motor control and coordination and is regulated with small-conductance calcium-activated potassium (SK) channels. Application of SK2/3 channel activator, NS13001, NS309 and CyPPA, on cerebellar slices of SCA2 (ataxin-2 58Q) mice revealed Purkinje cell firing activity improved to tonic firing ([@B109]). Additionally, ingestion of NS13001 in SCA2 mice had improved motor function and prevented Purkinje cell degeneration ([@B108]). Similarly, treatment with chlorzoxazone, an SK channel activator, rectified tonic firing of Purkinje cells in SCA 2 mice ([@B60]). This led to the clinical study of the safety and efficacy of treatment with chlorzoxazone and baclofen (GABA~A~ receptor agonist) in SCA1 ([@B22]).

The therapeutic efficacy of different SK channel activators has also been demonstrated in a preclinical animal models expressing mutations in voltage-gated calcium channel or polyQ expanded proteins including SCA3 ([@B134]; [@B226]; [@B190]; [@B69]). In contrast, treatments that inhibit voltage-gated potassium channels, such as aminopyridines, which are approved for the treatment of multiple sclerosis, can offer therapeutic potential through the restoration of Purkinje cell firing rate. Specifically, 4-aminopyridine and 3,4-diaminopyridine, were tested on SCA1 (ataxin-1 82Q) mice and found to correct Purkinje cell firing frequency, prevent Purkinje cell degeneration and increased BDNF levels within the cerebellum ([@B98]; [@B88]). Similarly, acute treatment of cerebellar slices from SCA6 (84Q) mice with 4-aminopyridine increased the precision of Purkinje cell firing ([@B101]). This finding was further confirmed *in vivo*, chronic 4-aminopyridine treatment yielding motor improvements and increased precision of Purkinje cell firing in SCA6 mice ([@B101]).

Treatments Aimed at Reducing Calcium Signaling {#S4.SS3}
----------------------------------------------

Evidence gathered from preclinical animal models of SCA have suggested treatment with calcium signaling blockers may also offer therapeutic benefit ([@B32]; [@B131]). One approach is treatment with dantrolene, a compound which inhibits RyanR-mediated release of Ca^2+^ from the endoplasmic reticulum ([@B32]; [@B131]). Chronic dantrolene treatment yielded improved motor performance and prevented cell death in transgenic SCA3 and SCA2 mice ([@B32]; [@B131]). In addition, virally mediated overexpression of the inositol 1,4,5-phosphatase enzyme (5PP), ameliorated abnormal Purkinje cell firing, rescued motor performance and reduced Purkinje cell degeneration in ataxin-2 58Q-expressing mice ([@B110]). Functionally, 5PP converts active IP3 to inactive IP2, inhibiting IP3R-mediated calcium signaling within Purkinje cells ([@B110]). Furthermore, treatments which that increase expression of calcium binding proteins, calbindin and parvalbumin, may offer therapeutic benefit by enhancing calcium handling capacity, limiting calcium-mediated toxicity ([@B23]).

One hypothesized mechanism of disease for SCA3 is increased activity of calcium-activated proteases, such as calpains, which induce proteolytic cleavage of the ataxin-3 protein, resulting in the formation of toxic ataxin-3 fragments ([@B115]; [@B92]). Calpain cleavage sites have been identified along the ataxin-3 protein, supporting the hypothesis of calpain-mediated ataxin-3 proteolysis ([@B228]). Overexpressing the endogenous calpain inhibitor, calpastatin, in SCA3 murine models prevent ataxin-3 proteolysis, reduce ataxin-3 positive inclusions and prevent neurodegeneration ([@B195]). Cellular and animal models of SCA3 have also investigated treatment using calpain inhibitor compounds (ALLN, calpeptin, MDL28170, BDA410) and proven success in reducing ataxin-3 cleavage fragments, ataxin-3 aggregation, improving aberrant locomotion and prevent neurodegeneration ([@B74]; [@B115]; [@B196]; [@B225]). One study went further to demonstrate calpain inhibition can remove ataxin-3 cleavage fragments through the protein quality control pathway, macroautophagy, ameliorating disease phenotypes in a zebrafish model of SCA3 ([@B225]).

Treatments Aimed at Reducing Glutamate-Induced Excitotoxicity {#S4.SS4}
-------------------------------------------------------------

Various studies have explored modulating glutamate levels as a therapeutic option in the SCAs affected by glutamate-induce excitotoxicity. One approach that can be utilized to reduce excessive glutamate release is to administer modulators of mGluR and GABA receptor function, effectively increasing or decreasing excitation or inhibition within the cerebellum.

Treatment with JNJ1625968, a negative-allosteric modulator (NAM) of mGluR1, has been reported found to rescue aberrant motor function in SCA1 mice, whilst reducing the prolonged mGluR1 activity of ataxin-1 82Q in *ex vivo* cerebellar slices expressing Purkinje neurons ([@B169]). In contrast, administration of JNJ1625968 treatment *in vivo* worsened the motor phenotype of ataxin-1 154Q mice ([@B154]). These contrasting findings may be due to differences in the treatment regime used, as 2.5 mg/kg JNJ1625968 was administered to symptomatic 30-week old mice in the [@B154] study, whilst the [@B169] study treated their SCA1 mice with 0.03 mg/kg JNJ1625968 at 12-weeks of age. Hence, the divergent effects of the treatment may be attributed to the different stages of disease progression that the treatment was applied. Additionally, Ro0711401, a mGluR positive-allosteric modulator, was found to improve motor function and increase Purkinje cell dendritic spine length ([@B154]). FDA-approved compound, nitazoxanide (mGluR1/5- NAM) has also been shown to modulate mGluR1 function, similar to wild-type levels *in vitro* modeling SCA44 ([@B227]).

Since certain SCAs have similar phenotypes of glutamate-induced excitotoxicity, riluzole has been extensively trialed in animal models as well as clinical trials. Riluzole is known to prevent glutamate release by inhibition of NMDA receptors and is a currently therapeutic option for amyotrophic lateral sclerosis ([@B54]). Whilst murine models of SCA1 and SCA3 did not show improvements in motor behavior, prolonged treatment with riluzole affected ataxin-3 proteinopathy by reducing soluble ataxin-3 and accumulating ataxin-3 in cortical cell bodies ([@B149]; [@B183]). Despite this, riluzole has been tested on SCA patients for safety and efficacy, providing minimal improvement in ataxic symptoms ([@B173]; [@B174]). More recently troriluzole (BHV-4157), a new prodrug of riluzole, was trialed in SCA1-3, SCA6-8 and SCA10 patients in a 48-week and 96-week open label clinical trial. Patients yielded improved SARA scores, suggesting a lack of disease progression during the treatment period ([@B15]; [@B229]). Additionally, memantine, an NMDA receptor antagonist, is another compound that has been trialed as a potential therapeutic in for the SCAs. Treatment of SCA1 (ataxin-1 154Q) knock-in mice treated with memantine proved effective by increasing lifespan, reduced ubiquitin positive neuronal inclusions and prevented Purkinje cell neurodegeneration ([@B94]).

Another therapeutic approach examined for the treatment of SCA1 was increasing inhibitory tone via GABA receptor activation. [@B194] found that a single dose of baclofen (GABA~B~ receptor agonist) directly into the cerebellum of SCA1 mice was sufficient to improving motor impairment and enhancing mGluR1 signaling between parallel fibers and Purkinje cells and prevent motor impairment. Furthermore, [@B35] demonstrated that combined treatment with baclofen and virally mediated overexpression of BK channels was more effective at increasing Purkinje cell calcium spiking thresholds and reducing motor impairments in ataxin-1 82Q expressing mice than treatment with baclofen alone. This suggests that perhaps combinatorial approaches which modulate glutamate release and other disease mechanisms may be more effective.

Concluding Remarks {#S5}
==================

There is a consensus within the field of spinocerebellar ataxia research that more basic science research is required to fully comprehend early disease mechanisms that occur early within the window of reversibility, before the onset of permanent cerebellar damage ([@B138]). Increased understanding of disease mechanisms will facilitate the development of new treatment strategies that target pathological changes which prior to neuronal damage and death ([@B138]). Whilst a single, unifying, pathogenic mechanism is yet to be identified, it is widely regarded that changes to transcriptional dysregulation, RNA toxicity, impaired proteostasis and altered neuronal signaling are common pathogenic themes across different types of SCA ([@B138]; [@B79]).

Despite rapid progress in the field of ataxia research and identification of causative genetic mutations, our understanding of precisely how genetic mutations cause insult to Purkinje cells and render cerebellar circuits defective remains limited ([@B91]). Interestingly, the consequences of recurrent pathogenic themes align with altered Purkinje cell function. Indeed, dysfunction of Purkinje cell firing has been identified as an early pathogenic hallmark in many SCAs, including SCA1 and SCA2 ([@B163]; [@B89]). Identified causes of perturbed Purkinje cell physiology include altered expression of genes critical to Purkinje cell function or development, altered expression or functionality of channels or receptors such as mGluR1, TRPC3 or IP3R1, and changes to excitatory tone, resulting from increased or decreased input from glutamatergic climbing or parallel fibers. As the sole output neuronal population within the cerebellar cortex, dysfunction of Purkinje cell integration can result in both increased and decreased activation of DCN-thalamus-motor cortex projections. Furthermore, impaired Purkinje cell function is thought to be characteristic of the early disease state, preceding motor impairments and toxicity ([@B191]; [@B89]).

Current treatment approaches aimed at rectifying Purkinje cell dysfunction include increasing gene expression through HDAC inhibitors, pharmacological manipulation of receptor or channel function, and removal of toxic protein species. Whilst current treatment approaches can alleviate disease symptoms and slow progression in preclinical animal models, clinical efficacy is yet to be determined. Therefore, it is beneficial to enhance understanding of disease mechanisms as compounds that correct aberrant physiology may offer enhanced therapeutic potential ([@B191]; [@B36]). Further elucidation of the changes that occur early in the disease process prior to toxicity, therapeutic approaches may be better placed to ultimately slow or halt disease progression ([@B36]; [@B138]; [@B163]).
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